LadRx Corporation (LADX)
USD 1.49
(-2.61%)
USD 1.49
(-2.61%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.3 Million USD | 2.72% |
| 2022 | 2.24 Million USD | -74.25% |
| 2021 | 8.72 Million USD | -27.64% |
| 2020 | 12.06 Million USD | -30.11% |
| 2019 | 17.25 Million USD | -24.74% |
| 2018 | 22.92 Million USD | -52.58% |
| 2017 | 48.34 Million USD | -22.98% |
| 2016 | 62.76 Million USD | -6.35% |
| 2015 | 67.02 Million USD | -21.79% |
| 2014 | 85.69 Million USD | 106.49% |
| 2013 | 41.5 Million USD | 3.15% |
| 2012 | 40.23 Million USD | 6.28% |
| 2011 | 37.85 Million USD | 3.15% |
| 2010 | 36.69 Million USD | 4.03% |
| 2009 | 35.27 Million USD | 24.55% |
| 2008 | 28.32 Million USD | -55.84% |
| 2007 | 64.14 Million USD | 102.76% |
| 2006 | 31.63 Million USD | 218.31% |
| 2005 | 9.93 Million USD | 96.86% |
| 2004 | 5.04 Million USD | -59.03% |
| 2003 | 12.32 Million USD | 32.75% |
| 2002 | 9.28 Million USD | 21.98% |
| 2001 | 7.61 Million USD | 10.95% |
| 2000 | 6.85 Million USD | 11.93% |
| 1999 | 6.12 Million USD | -63.08% |
| 1998 | 16.6 Million USD | -33.33% |
| 1997 | 24.9 Million USD | 2.47% |
| 1996 | 24.3 Million USD | -21.61% |
| 1995 | 31 Million USD | -19.9% |
| 1994 | 38.7 Million USD | -22.29% |
| 1993 | 49.8 Million USD | -5.68% |
| 1992 | 52.8 Million USD | 121.85% |
| 1991 | 23.8 Million USD | 1300.0% |
| 1990 | 1.7 Million USD | -86.29% |
| 1989 | 12.4 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 2.22 Million USD | -3.75% |
| 2024 Q2 | 893.9 Thousand USD | -59.76% |
| 2023 FY | 2.3 Million USD | 2.72% |
| 2023 Q3 | 3.06 Million USD | -23.02% |
| 2023 Q1 | 1.23 Million USD | -45.24% |
| 2023 Q4 | 2.3 Million USD | -24.72% |
| 2023 Q2 | 3.98 Million USD | 223.65% |
| 2022 Q4 | 2.24 Million USD | -33.51% |
| 2022 FY | 2.24 Million USD | -74.25% |
| 2022 Q1 | 6.56 Million USD | -24.78% |
| 2022 Q2 | 5.03 Million USD | -23.35% |
| 2022 Q3 | 3.37 Million USD | -32.84% |
| 2021 FY | 8.72 Million USD | -27.64% |
| 2021 Q2 | 9.3 Million USD | -12.43% |
| 2021 Q3 | 17.03 Million USD | 83.18% |
| 2021 Q1 | 10.62 Million USD | -11.93% |
| 2021 Q4 | 8.72 Million USD | -48.78% |
| 2020 Q1 | 16.82 Million USD | -2.51% |
| 2020 FY | 12.06 Million USD | -30.11% |
| 2020 Q2 | 15.62 Million USD | -7.09% |
| 2020 Q3 | 15.36 Million USD | -1.66% |
| 2020 Q4 | 12.06 Million USD | -21.53% |
| 2019 FY | 17.25 Million USD | -24.74% |
| 2019 Q3 | 19.96 Million USD | 0.11% |
| 2019 Q1 | 21.5 Million USD | -6.19% |
| 2019 Q2 | 19.94 Million USD | -7.27% |
| 2019 Q4 | 17.25 Million USD | -13.57% |
| 2018 FY | 22.92 Million USD | -52.58% |
| 2018 Q1 | 43.12 Million USD | -10.8% |
| 2018 Q4 | 22.92 Million USD | -30.03% |
| 2018 Q2 | 43.8 Million USD | 1.57% |
| 2018 Q3 | 32.76 Million USD | -25.2% |
| 2017 Q4 | 48.34 Million USD | -3.01% |
| 2017 Q3 | 49.84 Million USD | -14.57% |
| 2017 Q2 | 58.34 Million USD | 10.33% |
| 2017 Q1 | 52.88 Million USD | -15.74% |
| 2017 FY | 48.34 Million USD | -22.98% |
| 2016 Q4 | 62.76 Million USD | -1.78% |
| 2016 Q1 | 75.33 Million USD | 12.41% |
| 2016 Q2 | 60.33 Million USD | -19.92% |
| 2016 Q3 | 63.9 Million USD | 5.92% |
| 2016 FY | 62.76 Million USD | -6.35% |
| 2015 FY | 67.02 Million USD | -21.79% |
| 2015 Q1 | 73.76 Million USD | -13.92% |
| 2015 Q3 | 76.74 Million USD | 22.53% |
| 2015 Q2 | 62.63 Million USD | -15.09% |
| 2015 Q4 | 67.02 Million USD | -12.67% |
| 2014 Q3 | 96.8 Million USD | -8.31% |
| 2014 Q1 | 114.83 Million USD | 176.72% |
| 2014 Q4 | 85.69 Million USD | -11.48% |
| 2014 FY | 85.69 Million USD | 106.49% |
| 2014 Q2 | 105.58 Million USD | -8.06% |
| 2013 Q2 | 29.31 Million USD | -15.07% |
| 2013 FY | 41.5 Million USD | 3.15% |
| 2013 Q1 | 34.51 Million USD | -14.2% |
| 2013 Q4 | 41.5 Million USD | 69.62% |
| 2013 Q3 | 24.46 Million USD | -16.54% |
| 2012 Q3 | 24.35 Million USD | -14.57% |
| 2012 Q1 | 33.38 Million USD | -11.82% |
| 2012 FY | 40.23 Million USD | 6.28% |
| 2012 Q4 | 40.23 Million USD | 65.16% |
| 2012 Q2 | 28.51 Million USD | -14.58% |
| 2011 FY | 37.85 Million USD | 3.15% |
| 2011 Q3 | 44.86 Million USD | 53.72% |
| 2011 Q2 | 29.18 Million USD | -12.2% |
| 2011 Q1 | 33.24 Million USD | -9.4% |
| 2011 Q4 | 37.85 Million USD | -15.63% |
| 2010 Q3 | 41.78 Million USD | -4.64% |
| 2010 Q4 | 36.69 Million USD | -12.17% |
| 2010 Q1 | 35.77 Million USD | 1.41% |
| 2010 FY | 36.69 Million USD | 4.03% |
| 2010 Q2 | 43.81 Million USD | 22.48% |
| 2009 Q3 | 37.17 Million USD | 80.46% |
| 2009 FY | 35.27 Million USD | 24.55% |
| 2009 Q1 | 24.79 Million USD | -12.48% |
| 2009 Q2 | 20.59 Million USD | -16.9% |
| 2009 Q4 | 35.27 Million USD | -5.1% |
| 2008 FY | 28.32 Million USD | -55.84% |
| 2008 Q2 | 42.86 Million USD | -15.19% |
| 2008 Q4 | 28.32 Million USD | -20.76% |
| 2008 Q3 | 35.74 Million USD | -16.61% |
| 2008 Q1 | 50.53 Million USD | -21.21% |
| 2007 Q4 | 64.14 Million USD | -5.82% |
| 2007 Q1 | 38.07 Million USD | 20.34% |
| 2007 FY | 64.14 Million USD | 102.76% |
| 2007 Q2 | 72.67 Million USD | 90.89% |
| 2007 Q3 | 68.11 Million USD | -6.28% |
| 2006 Q2 | 14.43 Million USD | -22.75% |
| 2006 FY | 31.63 Million USD | 218.31% |
| 2006 Q1 | 18.68 Million USD | 88.04% |
| 2006 Q3 | 35.07 Million USD | 142.98% |
| 2006 Q4 | 31.63 Million USD | -9.81% |
| 2005 Q1 | 21.3 Million USD | 321.99% |
| 2005 Q2 | 17.35 Million USD | -18.55% |
| 2005 Q3 | 12.73 Million USD | -26.61% |
| 2005 FY | 9.93 Million USD | 96.86% |
| 2005 Q4 | 9.93 Million USD | -21.95% |
| 2004 FY | 5.04 Million USD | -59.03% |
| 2004 Q1 | 11.91 Million USD | -3.35% |
| 2004 Q4 | 5.04 Million USD | -14.3% |
| 2004 Q2 | 8.14 Million USD | -31.63% |
| 2004 Q3 | 5.89 Million USD | -27.66% |
| 2003 Q3 | 19.38 Million USD | 53.35% |
| 2003 Q4 | 12.32 Million USD | -36.44% |
| 2003 FY | 12.32 Million USD | 32.75% |
| 2003 Q1 | 8.41 Million USD | -9.32% |
| 2003 Q2 | 12.64 Million USD | 50.2% |
| 2002 Q2 | 6.77 Million USD | -10.9% |
| 2002 FY | 9.28 Million USD | 21.98% |
| 2002 Q3 | 11.14 Million USD | 64.5% |
| 2002 Q1 | 7.6 Million USD | -0.08% |
| 2002 Q4 | 9.28 Million USD | -16.71% |
| 2001 Q1 | 5.78 Million USD | -15.66% |
| 2001 FY | 7.61 Million USD | 10.95% |
| 2001 Q4 | 7.61 Million USD | 71.92% |
| 2001 Q3 | 4.42 Million USD | -7.6% |
| 2001 Q2 | 4.79 Million USD | -17.19% |
| 2000 Q4 | 6.85 Million USD | 24.56% |
| 2000 Q3 | 5.5 Million USD | -8.1% |
| 2000 FY | 6.85 Million USD | 11.93% |
| 2000 Q1 | 6.42 Million USD | 4.83% |
| 2000 Q2 | 5.99 Million USD | -6.72% |
| 1999 Q2 | 11.1 Million USD | -20.71% |
| 1999 FY | 6.12 Million USD | -63.08% |
| 1999 Q3 | 6.8 Million USD | -38.74% |
| 1999 Q1 | 14 Million USD | -15.66% |
| 1999 Q4 | 6.12 Million USD | -9.88% |
| 1998 Q4 | 16.6 Million USD | -25.23% |
| 1998 Q3 | 22.2 Million USD | -8.26% |
| 1998 Q1 | 22.6 Million USD | -9.24% |
| 1998 Q2 | 24.2 Million USD | 7.08% |
| 1998 FY | 16.6 Million USD | -33.33% |
| 1997 Q2 | 25.1 Million USD | 3.72% |
| 1997 Q4 | 24.9 Million USD | 1.63% |
| 1997 Q1 | 24.2 Million USD | -0.41% |
| 1997 FY | 24.9 Million USD | 2.47% |
| 1997 Q3 | 24.5 Million USD | -2.39% |
| 1996 FY | 24.3 Million USD | -21.61% |
| 1996 Q4 | 24.3 Million USD | -6.54% |
| 1996 Q1 | 29.3 Million USD | -5.48% |
| 1996 Q2 | 28.2 Million USD | -3.75% |
| 1996 Q3 | 26 Million USD | -7.8% |
| 1995 Q2 | 34.6 Million USD | -4.16% |
| 1995 Q4 | 31 Million USD | -6.06% |
| 1995 Q1 | 36.1 Million USD | -6.72% |
| 1995 FY | 31 Million USD | -19.9% |
| 1995 Q3 | 33 Million USD | -4.62% |
| 1994 Q2 | 44.3 Million USD | -4.94% |
| 1994 Q1 | 46.6 Million USD | -6.43% |
| 1994 Q4 | 38.7 Million USD | -10.62% |
| 1994 FY | 38.7 Million USD | -22.29% |
| 1994 Q3 | 43.3 Million USD | -2.26% |
| 1993 Q1 | 52.5 Million USD | -0.57% |
| 1993 Q2 | 51.8 Million USD | -1.33% |
| 1993 Q4 | 49.8 Million USD | -1.78% |
| 1993 Q3 | 50.7 Million USD | -2.12% |
| 1993 FY | 49.8 Million USD | -5.68% |
| 1992 Q1 | 48.7 Million USD | 104.62% |
| 1992 Q4 | 52.8 Million USD | 5.81% |
| 1992 Q2 | 49.5 Million USD | 1.64% |
| 1992 Q3 | 49.9 Million USD | 0.81% |
| 1992 FY | 52.8 Million USD | 121.85% |
| 1991 Q3 | 4.8 Million USD | 33.33% |
| 1991 FY | 23.8 Million USD | 1300.0% |
| 1991 Q1 | 2.6 Million USD | 52.94% |
| 1991 Q2 | 3.6 Million USD | 38.46% |
| 1991 Q4 | 23.8 Million USD | 395.83% |
| 1990 Q1 | 1.9 Million USD | -84.68% |
| 1990 Q3 | 2 Million USD | -9.09% |
| 1990 Q4 | 1.7 Million USD | -15.0% |
| 1990 Q2 | 2.2 Million USD | 15.79% |
| 1990 FY | 1.7 Million USD | -86.29% |
| 1989 FY | 12.4 Million USD | 0.0% |
| 1989 Q4 | 12.4 Million USD | 552.63% |
| 1989 Q3 | 1.9 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -99808.312% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -17.858% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 78.133% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -318.004% |
| Rebus Holdings, Inc. | 5000.00 USD | -46057.64% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 98.228% |
| Qrons Inc. | 420.00 USD | -549395.714% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -199.474% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 91.741% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -380.251% |
| Skye Bioscience, Inc. | 11.94 Million USD | 80.672% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 94.059% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 68.034% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -2922.608% |
| SQZ Biotechnologies Company | 107.18 Million USD | 97.847% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -61.161% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -3089.224% |
| Mesoblast Limited | 667.9 Million USD | 99.654% |
| Marizyme, Inc. | 22.01 Million USD | 89.517% |
| Genus plc | 1.02 Billion USD | 99.776% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -69.903% |
| Pharming Group N.V. | 462.85 Million USD | 99.501% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 30.339% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -362.465% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -268.083% |
| ContraFect Corporation | 20.67 Million USD | 88.839% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -491.21% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -503.878% |
| IMV Inc. | 31.33 Million USD | 92.635% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 44.335% |
| MultiCell Technologies, Inc. | 126.22 USD | -1828359.832% |
| ONE Bio Corp. | 70.08 Million USD | 96.707% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -145.601% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 98.204% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -434.586% |
| Q BioMed Inc. | 3.51 Million USD | 34.352% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 93.44% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -783.309% |
| Biomind Labs Inc. | 73.81 Thousand USD | -3026.406% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.483% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -59.291% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 92.311% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 15.965% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -235.699% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 11.344% |
| GB Sciences, Inc. | 103.44 Thousand USD | -2131.088% |
| Alpha Cognition Inc. | 2.45 Million USD | 5.884% |
| HST Global, Inc. | 1526.00 USD | -151137.353% |
| CSL Limited | 38.02 Billion USD | 99.994% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -133.599% |
| Halberd Corporation | 10.13 Thousand USD | -22680.397% |
| Enzolytics Inc. | 361.7 Million USD | 99.362% |
| Agentix Corp. | 261.39 Thousand USD | -782.92% |
| Resverlogix Corp. | 8.11 Million USD | 71.56% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -22.898% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.949% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 95.162% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -260.8% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -10030.732% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 74.211% |
| AVAX Technologies, Inc. | 7.37 Million USD | 68.716% |
| Zenith Capital Corp. | 7410.00 USD | -31045.506% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.932% |
| Ember Therapeutics, Inc. | 184.00 USD | -1254183.696% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -617.166% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -783.014% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -148.705% |
| Kadimastem Ltd | 2.3 Million USD | -0.165% |
| Helix BioMedix, Inc. | 3.02 Million USD | 23.709% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 95.621% |
| BioStem Technologies, Inc. | 14.56 Million USD | 84.149% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -3942.25% |
| Cell Source, Inc. | 195.17 Thousand USD | -1082.492% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -552.65% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -552.65% |
| NovAccess Global Inc. | 62.24 Thousand USD | -3607.56% |
| Affymax, Inc. | 7.44 Million USD | 68.993% |
| Itoco Inc. | 1.4 Million USD | -64.84% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -2312.664% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -2077.247% |
| Mobile Lads Corp. | 52.00 USD | -4438134.615% |
| CytoDyn Inc. | 11.13 Million USD | 79.275% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -1514.22% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -12807.617% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -498.717% |
| SYBLEU INC | 330.46 Thousand USD | -598.368% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -463.693% |
| International Stem Cell Corporation | 5.39 Million USD | 57.182% |
| Bioxytran, Inc. | 137.63 Thousand USD | -1576.777% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 84.616% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 86.079% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -2821.37% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -166.907% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 69.298% |
| Neutra Corp. | 2851.00 USD | -80849.912% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 92.878% |
| PureTech Health plc | 693.97 Million USD | 99.667% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 71.406% |
| IXICO plc | 15.84 Million USD | 85.434% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 72.134% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 97.766% |
| CSL Limited | 38.02 Billion USD | 99.994% |
| Cellectis S.A. | 333.99 Million USD | 99.309% |